Download Full Text (350 KB)
"Development of tumor resistance to chemotherapeutics is related to inherent tumor variations regarding sensitivity to chemotherapeutics and to sub-optimal dosing regimens, including variation in patient pharmacokinetics that result in suboptimal exposure of tumor cells to anti-neoplastic drugs [1, 2]. The rate and extent of drug efficacy depends on the extent of drug exposure at the tumor site and the time above the effective concentration . In vitro models that incorporate these pharmacokinetic and pharmacodynamic (PK/PD) principles to optimize therapeutic response may be considered the method of choice for optimizing dosing schedules before translating data from static assays to animals and clinical trials [4, 5]. The hollow fiber bioreactor was recently used to evaluate pharmacokinetic/pharmacodynamic (PK/PD) effects of gemcitibine in lung and breast cancers and to model HIV treatments [4-6]."
tumor resistance, chemotherapeutics, dosing regimens, pharmacokinetics, pharmacodynamics, PK/PD
Medicinal and Pharmaceutical Chemistry | Oncology | Other Chemicals and Drugs | Other Pharmacy and Pharmaceutical Sciences | Pharmaceutical Preparations | Pharmaceutics and Drug Design
Daniel Lexcen, Ahmed Salem, Walid M. El-Khatib, Virginia Haynes and Ayman Noreddin (2012). Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Anti-Neoplastic Agents, Readings in Advanced Pharmacokinetics - Theory, Methods and Applications, Dr. Ayman Noreddin (Ed.), ISBN: 978-953-51-0533-6, InTech, Available from: http://www.intechopen.com/books/readings-in-advanced-pharmacokinetics-theorymethods- and-applications/pharmacokinetic-pharmacodynamic-pk-pd-modeling-of-anti-neoplastic-agents
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Medicinal and Pharmaceutical Chemistry Commons, Oncology Commons, Other Chemicals and Drugs Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Pharmaceutical Preparations Commons, Pharmaceutics and Drug Design Commons